2026年欧洲肿瘤内科学会年会（ESMO Congress 2026）定于当地时间10月23日至27日在西班牙马德里举办。7月17日，ESMO官网已公布了除LBA之外的常规摘要标题及讲者信息。【肿瘤资讯】特此汇总整理了本次大会乳腺肿瘤方向入选Proffered Paper Session与Rapid Oral Session的核心临床研究，速览前沿学术亮点。
Proffered Paper session
摘要号：1842O
标题：Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
中文标题：Atirmociclib联合氟维司群治疗CDK4/6抑制剂经治HR+/HER2–晚期/转移性乳腺癌的疗效与安全性：随机Ⅱ期FOURLIGHT-1研究
讲者：Antonio Giordano (Boston, United States of America)
摘要号：4240O
标题：Spatial proteomic profiling of the myeloid tumor microenvironment in early triple-negative breast cancer (eTNBC) treated with neoadjuvant chemo-immunotherapy
中文标题：新辅助化疗联合免疫治疗后早期三阴性乳腺癌髓系肿瘤微环境的空间蛋白质组学特征分析
讲者：Matteo Maria Naldini (Milan, Italy)
摘要号：4242O
标题：Temporal Single-cell and Spatial Transcriptomics Reveal Neoadjuvant Chemotherapy Induced Tumour Ecosystem Dynamics in Early Breast Cancer
中文标题：时序单细胞转录组与空间转录组研究揭示新辅助化疗诱导的早期乳腺癌肿瘤生态系统动态变化
讲者：Jeremy Mo (Westmead, Australia)
Rapid Oral session
摘要号：1RO
标题：Overall survival from the Phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
中文标题：阿贝西利联合氟维司群对比安慰剂联合氟维司群治疗CDK4/6抑制剂经治HR+/HER2-晚期乳腺癌的总生存期：Ⅲ期postMONARCH试验
讲者：Kevin Kalinsky (Atlanta, United States of America)
摘要号：2RO
标题：Retrospective exploratory biomarker (BM) analyses from evERA Breast Cancer (BC): A Phase III trial of giredestrant (GIRE) + everolimus (E) in patients (pts) with oestrogen receptor-positive, HER2-negative advanced BC (ER+, HER2– aBC) in the post-CDK4/6 inhibitor (i) setting
中文标题：evERA乳腺癌试验的回顾性探索性生物标志物分析：giredestrant联合依维莫司治疗CDK4/6抑制剂经治ER+/HER2-晚期乳腺癌的Ⅲ期研究
讲者：Sara M. Tolaney (Boston, United States of America)
摘要号：3RO
标题：18F-FES PET–defined whole-body ER heterogeneity identifies endocrine responsiveness and predicts survival in ER+/HER2− Metastatic Breast Cancer (MBC): results of a prospective international clinical trial.
中文标题：18F-FES PET定义的全基因组雌激素受体异质性识别内分泌治疗反应性并预测ER+/HER2-转移性乳腺癌生存结局：一项前瞻性国际临床试验结果
讲者：Alessandra Gennari (Novara, Italy)
摘要号：4RO
标题：Target switching with conserved-payload novel ADCs in patients with metastatic breast cancer following prior ADC therapy (SWITCH): a prospective, open-label, phase 2 platform trial
中文标题：转移性乳腺癌ADC经治后采用同载荷新型ADC的靶点转换研究：一项前瞻性、开放标签的Ⅱ期平台试验（SWITCH）
讲者：刘西禹（复旦大学附属肿瘤医院）
摘要号：5RO
标题：Safety and efficacy of SYS6043, a Novel B7-H3–Targeting Antibody-Drug Conjugate, in Patients with Advanced breast cancer
中文标题：新型靶向B7-H3抗体药物偶联物SYS6043在晚期乳腺癌患者中的安全性与疗效
讲者：王红霞（复旦大学附属肿瘤医院）
摘要号：538RO
标题：Patient (pt)-reported outcomes (PROs) from the Phase III lidERA Breast Cancer (BC) trial of giredestrant (GIRE) in pts with oestrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC)
中文标题：Giredestrant治疗ER+/HER2–早期乳腺癌的Ⅲ期lidERA试验患者报告结局
讲者：Gustavo Werutsky (Porto Alegre, Brazil)
摘要号：539RO
标题：Patient-Reported Outcomes (PROs) From DESTINY-Breast05: Health-Related Quality of Life (HRQoL) With Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Patients (Pts) With High-Risk HER2-Positive Early Breast Cancer (eBC)
中文标题：DESTINY-Breast05研究患者报告结局：德曲妥珠单抗对比恩美曲妥珠单抗治疗高危HER2阳性早期乳腺癌患者的健康相关生活质量
讲者：Carlos H. Barrios (Porto Alegre, Brazil)
摘要号：540RO
标题：Ultrasensitive monitoring of early ctDNA dynamics during neoadjuvant treatment in early-stage triple-negative breast cancer: Pre-interim results from the B-STRONGER-I study
中文标题：早期三阴性乳腺癌新辅助治疗中超灵敏监测ctDNA的动态变化：B-STRONGER-I研究中期前结果
讲者：Carlos H. Barcenas (Houston, United States of America)
摘要号：541RO
标题：Hormone receptor (HR), PDL1, and stromal tumor-infiltrating lymphocytes (sTILs) predict pembrolizumab benefit in HER2-positive (HER2+) early stage breast cancer (EBC) in the phase II neoHIP trial
中文标题：激素受体、PD-L1及间质肿瘤浸润淋巴细胞预测帕博利珠单抗在HER2阳性早期乳腺癌中的获益：Ⅱ期neoHIP试验
讲者：David Page (Portland, United States of America)
摘要号：542RO
标题：Prognostic impact of postoperative ctDNA surveillance on relapse-free survival and molecular lead time in high-risk breast cancer: JCOG1204A1
中文标题：术后ctDNA监测对高危乳腺癌无复发生存期及分子领先时间的预后影响：JCOG1204A1
讲者：Yukinori Ozaki (Koto-ku, Japan)
摘要号：543RO
标题：DESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in HER2+ early breast cancer (eBC)
中文标题：DESTINY-Breast11：德曲妥珠单抗序贯紫杉醇+曲妥珠单抗+帕妥珠单抗 (THP) 对比剂量密集多柔比星+环磷酰胺序贯THP新辅助治疗HER2阳性早期乳腺癌的MRI评估客观缓解
讲者：Jean-Francois Boileau (Montreal, Canada, QC)
摘要号：544RO
标题：Final analysis of the GIM3 FATA trial: treatment schedule and three aromatase inhibitors (AIs) comparison in postmenopausal HR-positive (HR+) early breast cancer (eBC)
中文标题：GIM3 FATA试验最终分析：绝经后HR阳性早期乳腺癌中不同给药方案及三种芳香化酶抑制剂的比较
讲者：Pietro De Placido (Napoli, Italy)
摘要号：545RO
标题：Omission of adjuvant radiotherapy after breast-conserving surgery in systemically untreated older patients with early-stage estrogen receptor positive breast cancer: 5-year results of the TOP-1 study (BOOG 2016-01)
中文标题：未接受系统治疗的老年早期雌激素受体阳性乳腺癌患者保乳术后豁免辅助放疗：TOP-1研究（BOOG 2016-01）5年结果
讲者：Lotte Bouwman (Leiden, Netherlands)
摘要号：1766RO
标题：Health-Related Quality of Life from HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as 1L Maintenance Therapy for HER2+ mBC
中文标题：HER2CLIMB-05研究的健康相关生活质量：图卡替尼对比安慰剂联合曲妥珠单抗与帕妥珠单抗一线维持治疗HER2阳性转移性乳腺癌的Ⅲ期研究
讲者：Veronique C. Dieras (Rennes, France)
摘要号：1767RO
标题：BRIDGET: A Phase II trial of tucatinib added to trastuzumab/pertuzumab or ado-trastuzumab emtansine after isolated intracranial progression in patients with advanced HER2-positive breast cancer
中文标题：BRIDGET试验：晚期HER2阳性乳腺癌患者孤立性颅内进展后，图卡替尼联合曲妥珠单抗/帕妥珠单抗或恩美曲妥珠单抗治疗的Ⅱ期研究
讲者：Sarah Sammons (Boston, United States of America)
摘要号：1768RO
标题：Radiation Therapy Followed by Intrathecal (IT) Trastuzumab/Pertuzumab in the Management of HER2+ Breast Leptomeningeal Metastasis: Results from a Phase II Multi-Institutional Study, (INSPIRE-LM)
中文标题：放疗序贯鞘内注射曲妥珠单抗/帕妥珠单抗用于HER2阳性乳腺癌软脑膜转移治疗：多中心Ⅱ期INSPIRE-LM研究结果
讲者：Kamran Ahmed (Tampa, United States of America)
摘要号：1769RO
标题：CTC characterization with the DETECT CTC score predicts therapy response in triple-positive aBC: Translational results of the Phase III DETECT V Study
中文标题：基于DETECT CTC评分进行循环肿瘤细胞特征分析可预测三阳性晚期乳腺癌的治疗应答：III期DETECT V研究的转化研究结果
讲者：Kerstin Pfister (Ulm, Germany)
摘要号：1770RO
标题：Ultra-sensitive MRD Assessment in Long-term Complete Responders to Anti-HER2 Therapy in HER2-positive Metastatic Breast Cancer: Initial Results from HER2-CR Study
中文标题：HER2阳性转移性乳腺癌抗HER2治疗长期完全缓解者的超灵敏微小残留病灶检测：HER2-CR研究初步结果
讲者：Kazuki Nozawa (Nagoya, Japan)
摘要号：4639RO
标题：Final OS analysis of sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: Phase III OptiTROP-Breast01
中文标题：芦康沙妥珠单抗对比化疗治疗经治局部复发或转移性三阴性乳腺癌的最终总生存分析：Ⅲ期OptiTROP-Breast01研究
讲者：樊英（中国医学科学院肿瘤医院）
摘要号：4640RO
标题：Bulumtatug Fuvedotin (BFv, 9MW2821), a Nectin-4–Directed Antibody-Drug Conjugate (ADC), in Patients with Locally Advanced or Metastatic Triple Negative Breast Cancer (la/mTNBC) Previously Treated with Topoisomerase I Inhibitor (TopI)-Based ADCs: Results from a Phase 2 Study
中文标题：一种靶向Nectin-4的抗体药物偶联物Bulumtatug fuvedotin (BFv, 9MW2821)，用于既往接受过拓扑异构酶Ⅰ抑制剂类ADC治疗的局部晚期或转移性三阴性乳腺癌患者：一项Ⅱ期研究结果
讲者：张剑（复旦大学附属肿瘤医院）
排版编辑：肿瘤资讯-slb
苏公网安备32059002004080号
